Jump to content


  • Content Count

  • Joined

  • Last visited

  • Days Won


dydo last won the day on January 14

dydo had the most liked content!

Community Reputation

1,566 Excellent


About dydo

Profile Information

  • Location :


  • Portfolio %

Recent Profile Visitors

17,533 profile views
  1. I do not know about this lawsuit, but I would be careful with ham acting before at least the guilt is proven not aleged. Last time lawsuits were made it was a dying grasp of a company which could not manage itself from bankruptcy. This could be the case here considering the conditions and the timing. Let the courts decide.
  2. According to the proxy for the purpose of the general meeting, the issuance of the stock is addressed as follows: "As of the close of business on March 20, 2020, of our 160,000,000 authorized shares of common stock, there were 116,211,355 shares of common stock issued and outstanding. In addition to the 116,211,355 shares of common stock outstanding on March 20, 2020, there were 24,420,157 shares reserved for issuance pursuant to that certain stock purchase agreement we entered into on February 26, 2020 with Biogen MA, Inc. and the remainder of our authorized shares of common stock as of the close of business on March 20, 2020 have all been reserved for issuance under our various equity compensation plans, including the 2018 Plan. Accordingly, at present, there are no available unissued and unreserved authorized shares of our common stock, including to give effect to the proposed Share Reserve Amendment with respect to the Amended 2018 Plan that is part of Proposal No. 3. In this regard, the effectiveness of the Share Reserve Amendment and the ISO Limit Amendment that are part of Proposal No. 3 are contingent upon approval of this Proposal No. 4 by our stockholders." As it has been inaccurately stated elsewhere, the Biogen deal is not based on additional issuance of shares through this proposal. The change to the incentive plan from 2018 to 2020, is argued to have 9.9M shares addition, and that is the sole reason. Although a common practice, it is rather insensitive to require doubling of the shares. So having $600M, including the burn for the first quarter, literally is not enough to carry the company, even though $275M from Pfizer is being heralded as being on a cusp, and needing time. The $6.3B is not also considered as a potential income? Why this meeting not one in 2021 or 2022? Why not ask for 20M shares? The fiscal discipline has been mediocre, and it will continue having approved 160M shares. The incentive plan simply asks for 50% more shares to be awarded yearly. Why? I would not mind if they were buying those optioned shares. Macrae has 1M in options but owns zero. It is ATM, nothing else. I am going to vote no. This does not threaten the Biogen deal. And perhaps if it is because Biogen will not pay $9.21 per share and the management is ok to change the volume of shares to a larger amount than 24M.
  3. I doubt we will see 10, but if we do I will buy shares.
  4. Shorts cover 1m shares after Biogen deal. 16.5M shorts remain.
  5. 140M shares after the Biogen transaction, I think the company needs to be sensible how they hand out options. I will likely vote no to this proposal. They need to manage with reasonable expectations in those no so reasonable times.
  6. Sangamo's GM to take place on May 18th. Asking to double the shares availability as they are short with 160M to cover options, 24M to Biogen etc.
  7. As some know I have moved my interests into gene therapy and edit stocks. I wrote couple of articles about Sangamo Therapeutics on SA https://seekingalpha.com/article/4325158-despite-skepticism-sangamo-is-buy and this one https://seekingalpha.com/article/4328714-deal-biogen-boosts-recommendation-to-buy-sangamo-shares Those who are interested to discuss Sangamo on the board here, are welcome to join. This board is free and remains semi-monitored so no garbage gets in.
  8. 2017 pricing, perhaps going lower to $10? Maybe getting back here.
  9. SO what you guys think? after hours 15% drop, will it open 20% down or flat?
  10. dydo

    Beyond Solar

    Portola is purely the revenue growth story. If think of the revenue of $100M in 2019, the PE is about 10. In my opinion there is a potential for recovery beyond 20 but patience would be advisable. Too many shortsellers are crowding the stock. I do not own it for sometime. I am to engaged elsewhere and do not have cash. If I did I likely would buy to see where it goes. Proceed with caution
  11. dydo

    Beyond Solar

    No idea. I think the transparency behind some of the moves are pressing the shares as timelines allow shorts to act.
  12. dydo

    Beyond Solar

    Sangamo 2020 pipeline slide
  • Create New...